@article{b1b41ba3ea524a86bc23e622aa580e89,
title = "MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic",
abstract = "Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.",
keywords = "ACVR1, JAK inhibitor, Phase III clinical trial, anemia, danazol, hemoglobin, momelotinib, myelofibrosis, transfusion",
author = "Srdan Verstovsek and Chen, {Chih Cheng} and Mikl{\'o}s Egyed and Martin Ellis and Laura Fox and Goh, {Yeow T.} and Vikas Gupta and Claire Harrison and Kiladjian, {Jean Jacques} and Lazaroiu, {Mihaela C.} and Adam Mead and Donal McLornan and McMullin, {Mary F.} and Oh, {Stephen T.} and Andrew Perkins and Uwe Platzbecker and Christof Scheid and Alessandro Vannucchi and Yoon, {Sung Soo} and Kowalski, {Mark M.} and Mesa, {Ruben A.}",
note = "Funding Information: The study was sponsored by Sierra Oncology, Inc. The authors C-C Chen, M Egyed, M Ellis, YT Goh, MC Lazaroiu and C Scheid have no potential conflict of interest to declare. S Verstovsek received honoraria and research funding from Sierra Oncology and research funding from Incyte Corporation, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma Corp., Genentech, Blueprint Medicines Corp., Novartis, Pharma Essentia, AstraZeneca, Ital Pharma, Protagonist Therapeutics, Constellation Pharmaceuticals, Kartos Therapeutics, Prelude Therapeutics, AbbVie, Inc., Telios Pharmaceuticals and Galecto. L Fox participated in advisory boards for Novartis and served in a volunteer capacity as a member of the Gemfin board. V Gupta received honoraria from Sierra Oncology, Celgene and Pfizer, and research funding plus honoraria from Novartis. C Harrison was a consultant for Galacteo, Sierra Oncology, Constellation, Promeditor and Geron; was a consultant, received honoraria and participates in speaker{\textquoteright}s bureau for Cel-gene and Novartis; was a consultant and participated in speaker{\textquoteright}s bureau for CTI; was a consultant for and received honoraria from Roche; received honoraria from AOP Pharma; participated in speaker{\textquoteright}s bureau for Jannsen. J-J Kiladjian received research funding and participates in advisory boards for Novartis and AOP Orphan. A Mead was a consultant for AbbVie; is a consultant, received honoraria and research funding and participated in speaker{\textquoteright}s bureau for Novartis; was a consultant and received research funding from Celgene and BMS; received research funding and honoraria from CTI. D McLornan received travel bursary and speaker fees and participated in advisory boards for Jazz Pharmaceuticals; received speaker fees and participated in advisory boards for Novar-tis; and participated in advisory boards for Celgene/BMS. MF McMullin participated in advisory Boards for Daiiyo Sanyo, Astellas, Celgene and AbbVie; received speaker fees from Novartis and Jazz Pharmaceuticals. ST Oh was a consultant and participated in advisory boards for Novartis, Kartos Therapeutics, CTI BioPharma, Celgene/Bristol Myers Squibb, Disc Medicine, Blueprint Medicines, PharmaEssentia, Constellation and Incyte. A Perkins received honoraria Novartis and participates in MPN Advisory Boards for No-vartis and Kartos Therapeutics. U Platzbecker was a consultant and received research funding from Celgene and Novartis, and received research funding from Amgen, Janssen Biotech and Merck. A Vannucchi participated in speaker{\textquoteright}s bureau and had membership on the Board of Directors or advisory committees for Novartis, BMS/Celgene and AbbVie; membership on the Board of Directors or advisory committees for Blueprint and Incyte. S-S Yoon had a consulting or advisory role for Takeda, Amgen, Astellas, Celgene, Chugai, Janssen, Novartis; received honoraria from Novartis and Amgen; received research funding from Kyowa Kirin, Roche-Genentech and Yuhan Pharmaceutical. M Kowalski was employed by and held stock in Sierra Oncology. RA Mesa was a consultant for Novartis, Sierra Oncology and LaJolla, and received research support from Celgene, Incyte, AbbVie, Samus, Genetech, Promedior and CTI. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Andrew Dye, an employee of Sierra Oncology, provided medical writing support for the manuscript. Publisher Copyright: {\textcopyright} 2021 Future Oncology. All rights reserved.",
year = "2021",
month = apr,
doi = "10.2217/fon-2020-1048",
language = "English (US)",
volume = "17",
pages = "1449--1458",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "12",
}